Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorio Reig JofreXMAD:RJF +1.13%81 Equity-to-Asset is 0.53 as of Jun. 2026, which is 12% below its 10-year median of 0.60. GuruFocus rates XMAD:RJF with a GF Score™ of 81/100 and a GF Value™ of €2.69 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Laboratorio Reig Jofre ranks worse than 61.49% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Laboratorio Reig Jofre Equity-to-Asset Related Terms
Laboratorio Reig Jofre Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Laboratorio Reig Jofre's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:RJF vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Reig Jofre Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Laboratorio Reig Jofre's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Laboratorio Reig Jofre's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorio Reig Jofre (XMAD:RJF) has a Equity-to-Asset of 0.53 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Laboratorio Reig Jofre and its competitors. This is 12% below median its historical median of 0.60. Over the past decade, Laboratorio Reig Jofre's Equity-to-Asset has ranged from 0.53 to 0.70. According to the industry distribution chart, Laboratorio Reig Jofre ranks #618 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 61.5%.
Is Laboratorio Reig Jofre's Equity-to-Asset too high?
Laboratorio Reig Jofre's current Equity-to-Asset of 0.53 is 12% below median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 0.70. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Laboratorio Reig Jofre's value of 0.53 is 11.7% below this industry median. Based on the distribution chart, Laboratorio Reig Jofre ranks #618 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorio Reig Jofre has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Reig Jofre's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorio Reig Jofre ranks #618 out of 1005 companies for Equity-to-Asset. This places Laboratorio Reig Jofre in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Laboratorio Reig Jofre's value of 0.53 is 11.7% below this benchmark. Historically, Laboratorio Reig Jofre's own Equity-to-Asset has ranged from 0.53 to 0.70 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.60, Laboratorio Reig Jofre has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorio Reig Jofre's current Equity-to-Asset of 0.53 is 11.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Laboratorio Reig Jofre and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorio Reig Jofre's current Equity-to-Asset is 0.53, which is 12% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Reig Jofre stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Reig Jofre (XMAD:RJF) is currently considered Fairly Valued. The stock's GF Value™ is €2.69, compared to a current price of €2.69 — trading right at its estimated fair value. The current Equity-to-Asset is 0.53, which is 12% below median its 10-year median of 0.60 and 11.7% below the Drug Manufacturers industry median of 0.60. Laboratorio Reig Jofre's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Laboratorio Reig Jofre (XMAD:RJF), the current Equity-to-Asset is 0.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Reig Jofre (XMAD:RJF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued.
The current stock price of €2.69 is trading 0% below its estimated GF Value™ of €2.69.
GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.
Key valuation signals for XMAD:RJF:
Equity-to-Asset: 0.53 (12% below median its 10-year median of 0.60)
GF Value™: €2.69 vs. price of €2.69 (0% below fair value)
Industry Position: 11.7% below the Drug Manufacturers median (#618 of 1005)
No single metric tells the full story. See the XMAD:RJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
81GF Score
Get the complete analysis for XMAD:RJF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:RJF has been successfully added to your 
